Legend Biotech names Alan Bash interim CEO after Ying Huang resigns

• Legend Biotech CEO Ying Huang resigned as CEO, stepped down from the board, effective July 24, 2026.
• Huang plans to stay on as an adviser through August to support the transition; the departure was not tied to disputes.
• Alan Bash was named interim CEO, effective July 24, 2026; he has led CARVYKTI as president since October 2024.
• Bash previously served as CEO of ZielBio, led Checkmate Pharmaceuticals, spent 1999-2022 at Bristol Myers Squibb.
• Legend launched a search for a permanent CEO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316760), on July 27, 2026, and is solely responsible for the information contained therein.